Adoption of thulium fiber laser for lithotripsy
A scoping review and bibliometric analysis
DOI:
https://doi.org/10.5489/cuaj.9500Keywords:
ureteroscopy, laser, Thulium, Ho:YAG, PCNLAbstract
Introduction: While Holmium:YAG for laser lithotripsy remains the gold standard, the thulium fibre laser (TFL) has gained traction as a tool in urolithiasis management. The objective of this study was to review its adoption and use as a clinically effective laser lithotrite.
Methods: We performed a scoping review for articles on TFL for lithotripsy according to Preferred Reporting Items for Systematic reviews and Meta-Analyses Extension for Scoping Reviews (PRISMA-ScR). Available clinical outcomes and pre-clinical processes from studies were extracted. A bibliometric analysis was performed to outline and visualize publication trends overall and between clinical vs. pre-clinical studies. The review was registered in the International Prospective Register of Systematic Review (CRD42022300788).
Results: We identified a total of 107 studies using TFL for lithotripsy, 38 of which were clinical including 2803 patients, and 69 pre-clinical. Of the clinical studies, 26 (68%) were prospective and 29 (76%) involved ureteroscopic management of stones compared to 11 (29%) percutaneous nephrolithotomy. Complications rates remained acceptable between 032% and stone-free rates varied from 61100%. Tissue damage from TFL varied from 08%. Bibliometric analyses showed a rise in publications after 2020 in both clinical and pre-clinical work, with the U.S. (34%) then Russia (12%) as the leading countries, and the Journal of Endourology (24%) then World Journal of Urology (23%) being the leading venues.
Conclusions: By unifying clinical outcomes and pre-clinical insights, this review showed the maturation of TFL into an effective, versatile lithotripsy modality with accelerating global uptake. Further evidence is required to better characterize remaining clinical variability, lack of standardized outcome definitions, and cost-effectiveness analyses.
Downloads
Downloads
Published
How to Cite
Issue
Section
License
You, the Author(s), assign your copyright in and to the Article to the Canadian Urological Association. This means that you may not, without the prior written permission of the CUA:
- Post the Article on any Web site
- Translate or authorize a translation of the Article
- Copy or otherwise reproduce the Article, in any format, beyond what is permitted under Canadian copyright law, or authorize others to do so
- Copy or otherwise reproduce portions of the Article, including tables and figures, beyond what is permitted under Canadian copyright law, or authorize others to do so.
The CUA encourages use for non-commercial educational purposes and will not unreasonably deny any such permission request.
You retain your moral rights in and to the Article. This means that the CUA may not assert its copyright in such a way that would negatively reflect on your reputation or your right to be associated with the Article.
The CUA also requires you to warrant the following:
- That you are the Author(s) and sole owner(s), that the Article is original and unpublished and that you have not previously assigned copyright or granted a licence to any other third party;
- That all individuals who have made a substantive contribution to the article are acknowledged;
- That the Article does not infringe any proprietary right of any third party and that you have received the permissions necessary to include the work of others in the Article; and
- That the Article does not libel or violate the privacy rights of any third party.







